Skip to main
PRTA

Prothena (PRTA) Stock Forecast & Price Target

Prothena (PRTA) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 56%
Hold 11%
Sell 11%
Strong Sell 0%

Bulls say

Prothena Corp PLC demonstrates a promising outlook due to its clinical pipeline addressing significant unmet medical needs, including amyloid diseases, neurodegenerative disorders, and inflammatory conditions. The company has guided expectations for generating up to $105 million in aggregate milestone payments by 2026 from collaborations with partners Novo Nordisk and Bristol-Myers Squibb, suggesting strong financial potential. Additionally, while there are concerns regarding ARIA incidence related to specific treatments, other therapeutic candidates, such as PRX012, have shown favorable tolerability and reduced amyloid levels, enhancing the overall attractiveness of the company’s product portfolio.

Bears say

Prothena Corp PLC faces a challenging financial outlook due to continuous net losses expected until product approval and commercialization, coupled with the financial necessity of raising additional capital, which could dilute shareholder value. The company's clinical pipeline, while promising, is further complicated by elevated ARIA levels observed in its PRX012 candidate and the potential for changing regulatory dynamics that could impose new barriers to drug approval. Additionally, uncertainties surrounding the efficacy of its investigational therapeutics and the associated regulatory risks contribute to an overall negative sentiment regarding the company’s future financial performance.

Prothena (PRTA) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Prothena and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Prothena (PRTA) Forecast

Analysts have given Prothena (PRTA) a Buy based on their latest research and market trends.

According to 9 analysts, Prothena (PRTA) has a Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Prothena (PRTA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.